Hormonal
Reducing insulin resistance, rather than strictly lowering blood glucose, is the primary mechanism for reducing cardiovascular risk in type 2 diabetes.
For patients with Type 2 Diabetes, focusing solely on lowering blood sugar may not be enough to protect your heart. The key to reducing cardiovascular risk is improving your body's sensitivity to insulin. This can be achieved through lifestyle changes (weight loss, diet, exercise), specific medications like Metformin or Pioglitazone, or newer drugs like GLP-1 agonists (e.g., Liraglutide) and SGLT2 inhibitors (e.g., Empagliflozin), which offer cardiovascular benefits beyond glucose control.
The potential to reduce the risk of cardiovascular disease is determined not only by effective lowering of glucose but also by the ability to lower insulin resistance, which causes a paradigm shift in the management of type 2 diabetes.
Why this rating
Supported by multiple large-scale clinical trials (UKPDS, PROactive, IRIS, LEADER, EMPA-REG OUTCOME) and fundamental mechanistic studies.
Source
Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies
В. В. Салухов et al. · Diabetes Mellitus · 2018
DOI 10.14341/dm9570
More from this paper
- Thiazolidinediones (specifically Pioglitazone) significantly reduce cardiovascular events (stroke, MI, mortality) in patients with Type 2 Diabetes and macroangiopathies or recent stroke/TIA, independent of glucose lowering.Strong
- GLP-1 receptor agonists (e.g., Liraglutide) and SGLT2 inhibitors (e.g., Empagliflozin) reduce cardiovascular mortality in Type 2 Diabetes patients, primarily through mechanisms involving insulin sensitivity and weight loss rather than direct glucose lowering.Strong
- Intensive lifestyle modification (diet and exercise) reduces cardiovascular risk in Type 2 Diabetes patients, but long-term maintenance of weight loss is difficult, and significant risk reduction is only seen in those who maintain >10% weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →